NEW YORK – ERS Genomics said on Wednesday that it has granted Japanese drug maker Otsuka Pharmaceutical a license to its CRISPR-Cas9 patent portfolio, which Otsuka said it will use for its internal research and development programs to address areas of unmet medical need.
Financial and other terms of the deal were not disclosed.